Sanofi Begins Building Chinese Plant For Flu Vaccines
This article was originally published in PharmAsia News
Construction has begun in China on a factory being built by Sanofi Pasteur, expected to completed within four years. Sanofi intends the $102 million plant in Shenzhen to produce seasonal influenza vaccines for Chinese as well as prepare for a flu pandemic. The plant expects to produce as many as 25 million doses of vaccine annually by 2012, and double that amount within another three years. (Click here for more
You may also be interested in...
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.